An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $25 billion in 2050–from the… [ Get More Details ]
An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment… [ Get More Details ]
One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.
[ Get More Details ]
Slowing the Progress of Parkinson’s Disease Would Save Money
A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s… [ Get More Details ]